Hemodia

In 1985, in Toulouse, France, Pierre Montoriol founded Hemodia with a specific focus: producing custom lines for extracorporeal circuits for dialysis patients. The company's initial slogan, "Tailor-made immediately," captured its commitment to providing customized, responsive solutions for a critical healthcare need. For years, Hemodia grew by focusing on its core expertise in single-use medical devices, particularly for dialysis. This deep focus allowed them to build a reputation for quality and reliability. Recognizing the opportunity to leverage its manufacturing and design capabilities, the company expanded its product lines over time to include single-use care kits for applications like anesthesia and oncology, as well as plastic components and tubing for arthroscopy. A significant step in this evolution was the creation of a dedicated Research & Development department in 2014 to design and develop electrosurgical devices. A pivotal moment in Hemodia's journey came in 2019 when the private equity firm Ixo Private Equity, along with Bpifrance, acquired a majority stake. This move facilitated the transition from the founder, Pierre Montoriol, to a new management team led by CEO Rémi Teulière. The story continued in April 2025, when LBO France acquired a majority share, with historical investors like Bpifrance and Multicroissance reinvesting. This new partnership aims to accelerate Hemodia's international expansion, particularly in Europe, through strategic acquisitions, building on the company's strong foundation in the dialysis and medical device market.